The Board of Trustees of the Leland Stanford Junior University (USA)
The Regents of the University of California (USA)
The J.David Glastone Institutes,A Testamentary Trust Established under the Will of J.David Gladstone (USA)
Inventeur(s)
Porteus, Matthew H.
Cromer, Michael Kyle
Mackenzie, Tippi
Wienert, Beeke
Abrégé
The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBB locus in the HSPCs with a transgene encoding alpha globin.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A method and apparatus for operating a token-based vehicular security system (TVSS) is disclosed. The method includes communicating with a communicatively connected vehicle (CV) communicatively connected to the token based vehicular security system (TVSS); issuing a pseudonym certificate (PC) to the communicatively connected vehicle (CV) from one of a plurality of roadside units (RSUs) with the token-based vehicular security system (TVSS) having a low latency; and providing a standard unforgeability security guarantee for the token based vehicular security system (TVSS) without violating anonymity or unlinkability properties. The system includes a roadside unit (RSU) communicatively connected to a roadside unit backend included in a cloud computing environment; a certificate authority (CA) included in the cloud computing environment; a SETUP protocol; a TOKENGEN protocol; a PSEUDOGEN; and a REVOKE protocol.
B60R 25/24 - Moyens pour enclencher ou arrêter le système antivol par des éléments d’identification électroniques comportant un code non mémorisé par l’utilisateur
3.
III-NITRIDE-BASED HIGH EFFICIENCY AND HIGH-POWER DEVICES GROWN ON OR ABOVE A STRAIN RELAXED TEMPLATE
A method of growing III-nitride-based devices, such as light emitting diodes (LEDs) and laser diodes (LDs) on or above a strain relaxed template (SRT). The SRT uses a thin, thermally decomposed, InGaN underlayer, which is referred to as a decomposition layer (DL). Above the DL is a n-type GaN or low composition InGaN decomposition stop layer (DSL). A buffer layer comprising an n-type InGaN/GaN superlattice (SL) is then grown. For an LD structure. an n-type waveguide layer comprising a second n-type InGaN/GaN SL is then grown. followed by an active region, a p-type electron blocking layer (EBL), a p-type waveguide layer comprising a p-type InGaN/GaN SL, and p-type GaN or p-type InGaN layers. For an LED structure, the waveguide layers may be omitted. In this disclosure, AlGaN means AlxGa(1-x)N with 1≥x≥0 and InGaN means InxGa(1-x)N with 1≥x≥0.
H01S 5/20 - Structure ou forme du corps semi-conducteur pour guider l'onde optique
H01S 5/34 - Structure ou forme de la région activeMatériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p. ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH]
H01S 5/343 - Structure ou forme de la région activeMatériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p. ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH] dans des composés AIIIBV, p. ex. laser AlGaAs
H10H 20/815 - Corps ayant des structures de relaxation des contraintes, p. ex. des couches tampons
H10H 20/825 - Matériaux des régions électroluminescentes comprenant uniquement des matériaux du groupe III-V, p. ex. GaP contenant de l’azote, p. ex. GaN
4.
A GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
Disclosed herein are methods of treating arrhythmogenic right ventricular cardiomyopathy in a subject, comprising administering a gene therapy construct comprising a connexin 43 sequence, wherein as a result of the administration, connexin 43 levels in at least a portion of the heart are increased. Further disclosed are other cardiovascular diseases can be treated with the method.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present disclosure relates to CRISPR-Cas systems that utilize Cas12L for binding to and modifying nucleic acids in eukaryotic cells in a temperature regulated manner. Methods and compositions for using these CRISPR-Cas systems for editing nucleic acids for use in disease treatment and prevention in eukaryotic cells are provided herein.
Provided herein are nanoparticles comprising peptides that target checkpoint inhibitors such PD-1 as well as methods for their use. Peptides may be conjugated to nanoparticles such as cowpea mosaic virus or a cowpea chlorotic mottle virus. Nanoparticles provided herein display efficacy against tumors in a mouse model of disseminated and aggressive ovarian cancer.
Provided herein are methods of removing carbon dioxide from an aqueous stream or gaseous stream by: contacting the gaseous stream comprising carbon dioxide, when present, with an aqueous solution comprising ions capable of forming an insoluble carbonate salt; contacting the aqueous solution comprising carbon dioxide with an electroactive mesh that induces its alkalinization thereby forcing the precipitation of a carbonate solid from the solution and thereby the removal of dissolved inorganic carbon by electrolysis; and removing the precipitated carbonate solids from the solution, or the surface of the mesh where they may deposit. Also provided herein are flow-through electrolytic reactors comprising an intake device in fluid connection with a rotating cylinder comprising an electroactive mesh, and a scraping device and/or liquid-spray based device for separating a solid from the mesh surface.
B01D 53/78 - Procédés en phase liquide avec un contact gaz-liquide
C01B 13/36 - Méthodes de préparation des oxydes ou hydroxydes en général par réaction de précipitation en solution
C01B 32/60 - Préparation des carbonates ou des bicarbonates en général
C02F 1/461 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse
C02F 103/08 - Eau de mer, p. ex. pour le dessalement
C02F 103/18 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de l'épuration des effluents gazeux par voie humide
8.
PARTICLE-CONTAINING DROPLET SYSTEMS WITH MONODISPERSE FLUID VOLUMES
Systems and methods are described herein that create discrete volumes associated with solid-phase particles (e.g., drop-carrier particles) suspended in an immiscible phase (e.g., dropicles). One embodiment of the system includes a plurality of hydrogel-based drop-carrier particles containing a microscale voids or cavities that hold an aqueous phase droplet of fluid within each drop-carrier particle. The plurality of hydrogel drop-carrier particles associated with aqueous drops are suspended as individual elements in an immiscible oil phase. The microscale hydrogel drop-carrier particles containing the voids or cavities may be manufactured using microfluidic droplet generators. The dropicles may be used to analyze single-entities (e.g., single-molecules and single-cells) and analytes.
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
C09B 67/02 - Préparations tinctoriales caractérisées par un aspect physique particulier, p. ex. tablettes, feuilles
H01F 1/44 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriésEmploi de matériaux spécifiés pour leurs propriétés magnétiques en liquides magnétiques, p. ex. ferrofluides
9.
COMPOSITIONS AND METHODS FOR HYDROLYSIS OF SMOKE-ASSOCIATED GLYCOSIDICALLY-BOUND VOLATILE PHENOLS
The present disclosure provides compositions for hydrolyzing volatile phenols from phenolic glycosides. The disclosure also provides methods for utilizing the compositions to hydrolyze volatile phenols to remove volatile phenols from fruit products including fermented fruit products. Also provided herein are methods for measuring volatile phenols in fruit products including fermented fruit products.
C12G 1/14 - Préparation du vin ou du vin mousseux à faible teneur en alcool
A23L 2/84 - Clarification ou affinage des boissons non alcooliséesÉlimination des matières non désirées utilisant des micro-organismes ou un matériau biologique, p. ex. enzymes
C12C 11/11 - Traitements après fermentation, p. ex. carbonatation ou concentration
C12N 9/42 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-glucosidiques-1, 4, p. ex. cellulase
10.
HYBRID SERIES/PARALLEL PIEZOELECTRIC-RESONATOR BASED DC-DC CONVERTER
A DC-DC converter for converting an input voltage from a battery source includes a piezoelectric converter and a switched capacitor network between the battery source and the piezoelectric converter. The switched capacitor network provides a flying capacitor configured to be soft-charged and soft discharged due to an inductive operation of the piezoelectric converter such that charge-sharing loss of the flying capacitor is eliminated.
H02M 1/00 - Détails d'appareils pour transformation
H02M 3/00 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu
H02M 3/158 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs avec commande automatique de la tension ou du courant de sortie, p. ex. régulateurs à commutation comprenant plusieurs dispositifs à semi-conducteurs comme dispositifs de commande finale pour une charge unique
11.
SWITCHABLE GAS AND LIQUID RELEASE AND DELIVERY DEVICES, SYSTEMS, AND METHODS
Methods, systems, and devices are disclosed for implementing switchable dispensing and/or delivery of scented substances. In one aspect, a device includes a cartridge structured to include one or more chambers containing one or more scented substances contained in a corresponding chamber, a housing structured to include a compartment to hold the cartridge, an opening to allow the scented substances to dispense to an outer environment from the device, and one or more transporting channels formed between the compartment and the opening, in which each of the one or more transporting channels is configured to accelerate a scented substance from the corresponding chamber to the opening, and an actuator switch arranged in a corresponding transporting channel and operable to move between an open position and a closed position based on an applied signal to selectively allow passage of the scented substance from the corresponding transporting path.
A61L 9/04 - Désinfection, stérilisation ou désodorisation de l'air utilisant des substances gazeuses ou à l'état de vapeur, p. ex. de l'ozone utilisant des substances évaporées dans l'air sans chauffage
B05B 12/02 - Aménagements de commande de la distributionAménagements de réglage de l’aire de pulvérisation pour la commande de la durée ou de la succession des distributions
B05B 12/14 - Aménagements de commande de la distributionAménagements de réglage de l’aire de pulvérisation pour fournir à un orifice de pulvérisation unique, un liquide ou un autre matériau fluide choisi parmi plusieurs
G02C 11/00 - Accessoires non optiquesFixation de ceux-ci
The following relates generally to an implantable device (e.g., a device that is implantable to a human or animal subject). In some embodiments. the implantable device comprises a woven portion comprising two or more pluralities of threads woven together. Each of the pluralities of threads may be of a different thread type. Examples of types of threads include electrical wire. permeable tubing. optical fiber. polymer fiber, surface functionalized fiber. absorbable suture, and/or fiber comprising material configured for sensing. In some embodiments, the implantable device may be used to repair a lesion (e.g., a tumor).
In a Byzantine computing environment in which a database is sharded or partitioned among multiple clusters of computing nodes, consensus for and execution of data transactions (e.g., transactions that require and/or affect data of one or more shards) are achieved in a resilient manner. Within some clusters, multiple primary replicas concurrently propose transactions for processing in parallel by all replicas. For some multi-shard transactions, shards involved in the transactions may be logically ring-ordered; each shard in turn achieves consensus among its nodes to commit the transactions, and then executes its portion of the operation after consensus is obtained among all shards. For some other multi-shard transactions, involved shards first determine whether local data constraints are satisfied, after which data modifications are made in parallel.
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
H04L 9/00 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité
H04L 67/1095 - Réplication ou mise en miroir des données, p. ex. l’ordonnancement ou le transport pour la synchronisation des données entre les nœuds du réseau
H04L 67/1097 - Protocoles dans lesquels une application est distribuée parmi les nœuds du réseau pour le stockage distribué de données dans des réseaux, p. ex. dispositions de transport pour le système de fichiers réseau [NFS], réseaux de stockage [SAN] ou stockage en réseau [NAS]
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
The present disclosure provides compositions for hydrolyzing volatile phenols from phenolic glycosides. The disclosure also provides methods for utilizing the compositions to hydrolyze volatile phenols to remove volatile phenols from fruit products including fermented fruit products. Also provided herein are methods for measuring volatile phenols in fruit products including fermented fruit products.
A method of sensing attributes of an area, a scene or an entity of interest includes receiving at one or more receiving units a signal transmitted from one or more transmitting units, measuring one or more attributes of the received signal; and using, at least in part, wave diffraction principles for sensing. A method, system, and/or device for focusing signal waves, such as for RF field programming, via, at least in part, exploiting principles of diffraction.
G01S 13/89 - Radar ou systèmes analogues, spécialement adaptés pour des applications spécifiques pour la cartographie ou la représentation
H04B 7/06 - Systèmes de diversitéSystèmes à plusieurs antennes, c.-à-d. émission ou réception utilisant plusieurs antennes utilisant plusieurs antennes indépendantes espacées à la station d'émission
The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Methods and systems that provide data privacy for implementing a neural network-based inference are described. A method includes injecting stochasticity into the data to produce perturbed data, wherein the injected stochasticity satisfies an ε-differential privacy criterion and transmitting the perturbed data to a neural network or to a partition of the neural network for inference.
G06T 3/4046 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement utilisant des réseaux neuronaux
G06V 10/771 - Sélection de caractéristiques, p. ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
19.
Methods of Identifying and Treating Subjects having Inflammatory Subphenotypes of Asthma
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
20.
REAL-TIME MULTIRATE MULTIBAND AMPLIFICATION FOR HEARING AIDS
In accordance with a method for performing frequency subchannelization, a digital signal is received at an original sampling rate. A plurality of multirate frequency channels is produced by dividing the digital signal into an integer number of multirate frequency channels such that a sampling rate of each of the multirate frequency channels is proportional to a center frequency of the frequency channel. Signal processing is performed on each of the multirate frequency channels. The original sampling rate is reconstructed using the multirate frequency channels.
In certain embodiments, provided are methods for increasing the efficiency of dicot and gymnosperm transformation using BBM with no or minimal plant phenotype. Vector designs for achieving these results are also provided, as are methods for their use.
Substituted cyclodextrin complexes of closo-dodecaiodododecaborate and salts thereof are provided. Complexes according to certain embodiments are soluble in water sufficient to be used as an X-ray contrast agent. X-ray contrast agent compositions and methods for administering the complexes of closo-dodecaiodododecaborate are also described.
A61K 49/04 - Préparations de contraste pour rayons X
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
24.
Illumination Device for Spatial and Temporal Control of Morphogen Signaling in Cell Cultures
Provided are systems and methods for spatially and temporally controlling light with an illumination device comprising a light source operably connected to a circuit board, one or more light guide plates, one or more optical masks, a controller, and a computer readable medium, comprising instructions that, when executed by the controller, cause the controller to: illuminate a cell or a substrate with light from the light source, and spatially and temporally control illumination of light to the cell or the substrate with one or more illumination parameters, wherein the one or more light guide plates provides uniform illumination of the light. Also provided herein are methods of screening using the system and/or device of the present disclosure.
The Trustees of Columbia University in the City of New York (USA)
Universidad Autónoma de Madrid (Espagne)
Inventeur(s)
Zhang, Zhuolei
Skripka, Artiom
Schuck, P. James
Cohen, Bruce
Chan, Emory
Abrégé
Phonon engineered, lanthanide doped upconverting nanoparticles with very low phonon energies and tunable methods of synthesis that adjust OA:OM ratio and reaction temperature are provided. Low phonon energy KPb2X5 (X=Cl, Br) upconverting nanoparticles, both doped and undoped, exhibit dramatically suppressed multiphonon relaxation, enhancing upconversion emission from higher lanthanide excited states and enabling room temperature observation of avalanche like upconversion by Nd3+ ions. Intrinsic optical bistability (IOB) of the materials can provide bit level functionality to all optical computing. The IOB of Nd3+ doped nanocrystals, which are either bright or dark at the same excitation power based on power history, illustrate the functionality. High contrast switching and IOB are enabled via the photon avalanche process, which sustains population inversion between the ground and the first excited 4fN states of Nd3+ ions. The IOB of these nanocrystals can be controlled by temporal pump modulation and can store information.
C09K 11/77 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant des métaux des terres rares
C01F 17/36 - Composés contenant des métaux de terres rares et au moins un élément autre qu’un métal des terres rares, l'oxygène ou l'hydrogène, p. ex. La4S3Br6 le seul anion étant un halogénure, p. ex. NaYF4
Certain embodiments provide ligand-metal composite materials and compositions that could serve as catalyst-reductive agents to accelerate PFAS compounds defluorination. Certain embodiments provide optionally substituted 2,2′-bipyridine and 1,10-Phenanthroline ligand coordinated zero-valent metal as described herein and their use for defluorinating PFAS compounds.
In some embodiments, there is provided an apparatus for reflecting at least one millimeter wave beam, the apparatus includes a metasurface configured with a plurality of metal-backed dielectric cuboids, wherein each of the metal-backed dielectric cuboids includes a dielectric material having a first surface of the dielectric material and an opposite, second surface of the dielectric material, wherein the first surface of the dielectric material is in a same plane as the second surface of the dielectric material, wherein the dielectric material comprises a cuboid defined at least by a width and a thickness, and a metal layer having a first surface of the metal layer and an opposite second surface of the metal layer, wherein the second surface of the dielectric material is disposed on the first surface of the metal layer.
Disclosed is a sulfide-containing solid electrolyte material with an organic coating, as well as densified pellets containing this solid electrolyte material, a solid electrolyte thereof, and a solid state battery containing the solid electrolyte. According to aspects of the disclosure, the coating comprising a compound of Chemical Formula (1) or Chemical Formula (2) is formed on the surface of a sulfide-containing solid electrolyte material, e.g., the organic coating may comprise a compound having a thiol with a long hydrophobic tail, such as 1-undecanethiol. The coating provides densification of sulfide-containing solid electrolyte materials, and facilitates the ionic and lithium atomic diffusion coefficient at sulfide grain boundaries during pressing, thus achieving the densification of sulfide solid state electrolyte.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Biener, Juergen
Huang, Sijia
Feng, Longsheng
Ye, Jianchao
Ma, Meghann Christine
Li, Donglin
Wang, Kun
Kim, Sangil
Wan, Jiandi
Abrégé
A product, in accordance with one aspect of the present invention, includes a porous first layer having a first porosity, and a porous skin layer having a second porosity that is relatively lower than the first porosity. The skin layer is a self-formed layer. A method, in accordance with one aspect of the present invention, includes contacting a resin with a separator. The resin is exposed to radiation for curing the resin, thereby simultaneously creating a porous first layer and a porous skin layer positioned between the first layer and the separator. The first layer has a first porosity. The skin layer has a second porosity that is relatively lower than the first porosity.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 50/403 - Procédés de fabrication des séparateurs, des membranes ou des diaphragmes
H01M 50/414 - Résines synthétiques, p. ex. thermoplastiques ou thermodurcissables
H01M 50/449 - Séparateurs, membranes ou diaphragmes caractérisés par le matériau ayant une structure en couches
31.
Systems and Methods for Communicating by Modulating Data on Zeros in the Presence of Channel Impairments
Communication systems and methods in accordance with various embodiments of the invention utilize modulation on zeros. Carrier frequency offsets (CFO) can result in an unknown rotation of all zeros of a received signal's z-transform. Therefore, a binary MOCZ scheme (BMOCZ) can be utilized in which the modulated binary data is encoded using a cycling register code (e.g. CPC or ACPC), enabling receivers to determine cyclic shifts in the BMOCZ symbol remitting from a CFO. Receivers in accordance with several embodiments of the invention include decoders capable of decoding information bits from received discrete-time baseband signals by: estimating a timing offset for the received signal; determining a plurality of zeros of a z-transform of the received symbol; identifying zeros from the plurality of zeros that encode received bits by correcting fractional rotations resulting from the CFO; and decoding information bits based upon the received bits using a cycling register code.
A catalyst composition includes a liquid metal alloy having a melting point from about 20° C. to about 25° C., the liquid metal alloy including a primary metal and a secondary metal, the primary metal being aluminum and the secondary metal is selected from the group consisting of gallium, indium, and bismuth.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A method of diagnosis of Ménière's disease (MD) by performing genetic testing using a panel of gene mutations, including single nucleotide polymorphisms (SNPs), insertions and/or deletions (IN/DELs), in Ménière's disease-associated genes, providing genetic basis for MD. A method of treatment of MD by targeting the SNPs and/or IN/DELs gene mutations in Ménière's disease-associated genes, and/or by CRISPR or gene therapy or editing on the SNPs and/or IN/DELs gene mutations in Ménière's disease-associated genes.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present invention provides novel agents for modulation of Hv1 channels. The present invention provides agents for activating and/or inhibiting Hv1 channel function and/or activity, and reagents and methods relating thereto.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Described herein are compounds and methods for the modulation of AKT1 proteins, such as AKT1 E17K. In some aspects, the present disclosure provides an AKT1 protein, wherein a compound is bound to a lysine residue of the AKT1 protein. In another aspect, the present disclosure provides compounds of Formula (I) and (II), useful for the modulation of AKT1 proteins. In another aspect, the instant disclosure provides a method of attenuating AKT1 activity using the compounds described herein.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Provided herein are nuclear expressed antisense RNAs for interfering with a target repetitive RNA, the nuclear expressed antisense RNA comprising: (a) an oligonucleotide encoding an RNA-targeting guide comprising a sequence complementary to the target repetitive RNA; and (b) an oligonucleotide encoding a RNA binding protein (RBP)/ribonucleoprotein (RNP)-recruiting motif.
This disclosure provides systems, methods, and apparatus related to electrochemical reduction of gasses. In one aspect, a method includes flowing a gas through a reduction device. The gas is carbon dioxide (CO2) or nitrogen (N2). The reduction device reduces the gas and generates a product stream including the gas, hydrogen (H2), and a chemical. The product stream is flowed through a hydrogen removal device. The hydrogen removal device removes hydrogen from the product stream. The product stream with the hydrogen removed is flowed through the gas reduction device.
The present invention provides for a genetically modified host cell comprising a first polypeptide capable of active transport of urea into the host cell and/or a second polypeptide capable of degrading urea into ammonia and carbon dioxide, wherein the genetically modified host cell is capable of degrading urea into ammonia and carbon dioxide. The genetically modified host cell in a medium comprising urea, a calcium salt or calcium ion, and a phosphate is capable of producing calcium phosphate.
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
C07K 14/395 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de champignons provenant de levures provenant de Saccharomyces
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
C12N 9/80 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5) agissant sur les liaisons amides des amides aliphatiques
C12P 3/00 - Préparation d'éléments ou de composés inorganiques à l'exception du dioxyde de carbone
Techniques, systems and apparatus are described for magnetic resonance imaging. A method includes generating an MRI image by processing a first image obtained by applying a first order of modules including at least a first control module at a first time point and a first labeling module at a second time point to a target object, wherein the first control module inverts a magnetization of the target object and a second image obtained by applying a second order of modules including at least a second labeling module at a third time and a second control module at a fourth time to the target object, wherein the second labeling module inverts the magnetization of the target object.
G01V 3/00 - Prospection ou détection électrique ou magnétiqueMesure des caractéristiques du champ magnétique de la terre, p. ex. de la déclinaison ou de la déviation
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
43.
MILLIMETER-WAVELENGTH POWER AMPLIFIERS HAVING BOTH HIGH POWER GAIN AND HIGH OUTPUT POWER
A power amplifier (amp) includes a first transistor configured in the common source (CS) amplification mode, wherein the gate terminal of the first transistor is the input port of the power amp; and a second transistor configured in the common gate (CG) amplification mode, wherein the drain terminal of the second transistor is the output port of the power amp. The power amp also includes a first inductive component coupled between the drain terminal of the first transistor and the ground to increase the impedance between the drain terminal of the first transistor and the ground, thereby increasing an output power at the output port. The power amp additionally includes a second inductive component coupled between the drain terminal of the first transistor and the source terminal of the second transistor to increase the conductance in the output admittance at the output port, thereby further increasing the output power.
H03F 3/21 - Amplificateurs de puissance, p. ex. amplificateurs de classe B, amplificateur de classe C comportant uniquement des dispositifs à semi-conducteurs
Disclosed here are devices, systems, and methods for continuous monitoring of biomarkers using a wearable, non-intrusive microneedle sensor patch platform. In some aspects, a wearable, non-intrusive microneedle sensor device includes a microneedle sensor unit couplable to an electronics unit, where the microneedle sensor unit comprises a substrate, an array of spiked microneedle structures configured as electrochemical sensor electrodes, an array of base structures that encase a lower portion of spiked microneedle structures, and electrical interconnections that electrically couple the electrodes to the electronics unit for processing of detectable signals associated with one or multiple biomarkers in a biofluid.
A61B 5/1473 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des procédés chimiques ou électrochimiques, p. ex. par des moyens polarographiques invasifs, p. ex. introduits dans le corps par un cathéter
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
45.
COMPOSITIONS AND METHODS FOR MODULATING T CELL RESPONSES
In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for increasing HMGB2 (high-mobility group box2) activity in a T cell, for: increasing the rate or amount of differentiation and stemness of memory and exhausted CD8+ T cells in vivo, increasing the rate or amounts of effector and memory CD8+ T cells in vivo; expanding a subset of progenitor stem cells within an exhausted T cell population in vivo or ex vivo; boosting or increasing CD8+ T cells during acute viral infection in an individual in need thereof, increasing memory T cells and memory T cells differentiation, memory precursor effector (MPEC) and central memory (Tcm) T cell phenotypes, and memory recall responses in vivo, increasing the ability of an individual in need thereof to recover from a viral infection, and/or treating, ameliorating, slowing the progression of, decreasing the severity of symptoms of, an infection, optionally, a viral infection, in an individual in need thereof. In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for decreasing HMGB2 (high-mobility group box2) activity in a T cell, for: decreasing the rate or amount of differentiation and stemness of memory and exhausted CD8+ T cells in vivo, decreasing the rate or amounts of effector and memory CD8+ T cells in vivo; expanding a subset of progenitor stem cells within an exhausted T cell population in vivo or ex vivo; and/or treating, ameliorating, slowing the progression of, decreasing the severity of symptoms of, an autoimmune disease, in an individual in need thereof.
In some embodiments, a system for quantum key distribution, includes a plurality of n devices pairwise connected by an optical network, where n is an integer greater than or equal to 2. The optical network comprises a set of n(n−1) channels. The system employs wavelength-multiplexing, wavelength-demultiplexing, and time-multiplexing to provide a secure quantum key between two devices.
The invention disclosed herein provides methods and materials designed to improve organ transplantation outcomes. Embodiments of the invention include methods for administering the drug belumosudil to patients who have undergone an organ or other tissue transplantation (e.g., transplantation of a solid donor organ such as a kidney and/or receiving an infusion of donor stem cells such as CD34+ cells). In these methods, transplantation patients to whom belumosudil is administered are selected to be those not suffering from graft versus host disease (GVHD).
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
48.
DEEP-LEARNING BASED METHODS FOR VIRTUAL SCREENING OF MOLECULES FOR MICRO RIBONUCLEIC ACID (MIRNA) DRUG DISCOVERY
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Yuan, Jiann-Shiun
Keshavarzi Arshadi, Arash
Salem, Milad
Goodarzi, Hani
Abrégé
A method for training a deep learning model configured for virtual screening of molecules for micro ribonucleic acid (miRNA) drug discovery includes creating a training dataset including a plurality of assay datasets. The method also includes training the deep learning model to learn a plurality of tasks; performing, using the deep learning model, inference for the respective task associated with at least one miRNA assay dataset; and evaluating respective performance metrics associated with the respective predictions for each of the plurality of tasks. The method further includes selecting a set of the plurality of assay datasets for training; and training the deep learning model to learn a set of the plurality of tasks using the set of the plurality of assay datasets. The trained deep learning model is configured to predict molecules capable of affecting a target miRNA.
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
C40B 30/06 - Procédés de criblage des bibliothèques en mesurant les effets sur des cellules, des tissus ou des organismes vivants
The present invention provides for a nucleic acid encoding refactored minimized set of Agrobacterium virulence genes. The present invention provides for a method for introducing a nucleic acid of interest into a eukaryotic cell, the method comprises: (a) providing (i) a first nucleic acid encoding a refactored minimized set of Agrobacterium virulence genes operatively linked to one or more promoters; and (ii) a second nucleic acid comprising a nucleic acid of interest flanked by a left border and a right border; (b) introducing the first nucleic acid and the second nucleic acid into a target host cell; and, (c) the nucleic acid of interest is stably integrated into a genome of the target host cell.
Biocompatible and biodegradable polymers are provided herein as compositions, methods, and systems for making the compositions. These polymers can be adjustably stable and used in medical applications as adhesives and sealants, and in non-medical applications. Radical polymerization protocols, and two-step cationic and radical polymerization protocols, are provided for the creation of stable, polydisulfide polymers, which can be done in aqueous solution and at ambient and in vivo temperatures ranging, for example, from 0° C. to 37° C. The compositions are biocompatible and can be used as fast curing, biocompatible and biodegradable adhesives and sealants suitable for use in the consumer, industrial, military and medical arts, namely as a functional biomaterial, sustainable plastic, surgical superglue, bone adhesive, pressure-sensitive adhesive, structural adhesive, and other relevant sustainable materials with closed-loop recycling.
Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
Certain embodiments of the invention provide multifunctional materials (MFMs) comprising self-regenerative Ni-doped CaTiO3/CaO for the integrated CO2 capture and dry reforming of methane (ICCDRM), where CaO is a sorbent for CO2 capture and Ni-doped CaTiO3 is a catalyst, to convert two greenhouse gases (CO2 and CH4) into syngas (CO and H2). The incorporation of Ni into CaTiO3 and in-situ exsolution of Ni from CaNixTi1−xO3 were investigated. In-situ exsolved Ni nanoparticles, which interact strongly with the host CaTiO3 perovskite, are evenly distributed throughout the CaTiO3 under reductive conditions (e.g., under H2). The exsolved Ni nanoparticles re-dispersed back into the bulk of CaTiO3 under CO2 (oxidative condition). Ni-doped CaTiO3/CaO MFMs show relatively stable CO2 capture capacity and syngas productivity during 30 cycles of ICCDRM.
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
This disclosure provides systems, methods, and apparatus related to a stacked dual cathode device. In one aspect, a device includes an anode chamber and a cathode chamber. The anode chamber includes an anode layer. The cathode chamber includes a first cathode layer and a second cathode layer. The device further includes an ion exchange membrane. The anode layer is in contact with a first side of the ion exchange membrane. A first side of the first cathode layer is in contact with a second side of the ion exchange membrane. The cathode chamber further includes a conductive membrane. A first side of the conductive membrane is in contact with a second side of the first cathode layer and a second side of the conductive membrane is in contact with a first side of the second cathode layer.
C25B 9/23 - Cellules comprenant des électrodes fixes de dimensions stablesAssemblages de leurs éléments de structure avec des diaphragmes comprenant des membranes échangeuses d'ions dans ou sur lesquelles est incrusté du matériau pour électrode
Aspects of the disclosure relate to novel scFv molecules that are useful for incorporation into novel chimeric antigen receptors with enhance anti-tumor activity. Further aspects relate to a polypeptide comprising a CAR comprising, in order from amino proximal to carboxy proximal end, a scFv, a transmembrane domain, a torsional linker, and a cytoplasmic region comprising a primary intracellular signaling domain, wherein the torsional linker comprises 1-12 alanine residues. Also described are nucleic acids comprising a sequence encoding a polypeptide of the disclosure, vectors, such as lentiviral vectors comprising the nucleic acids of the disclosure, cells comprising and/or expressing nucleic acids and/or polypeptides of the disclosure, and populations of cells comprising the cell embodiments of the disclosure. Also provided are methods of making cells that express a polypeptide and methods of treating patients with the polypeptides and cell compositions of the disclosure.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.
A system for a multi-chambered electrochemical cell for carbon dioxide removal includes an electrochemical cell. The electrochemical cell includes an anodic chamber at a first end of the electrochemical cell, which includes an anode. The electrochemical cell includes an acid swing chamber adjacent to the anodic chamber and separated by a cation exchange membrane. The electrochemical cell includes a desalination chamber separated from the acid swing chamber by a anion exchange membrane. The electrochemical cell includes a base swing chamber in fluid communication with the acid swing chamber and the desalination chamber. The base swing chamber is adjacent to the desalination chamber and separated by a cation exchange membrane. The electrochemical cell includes a cathodic chamber at a second end of the electrochemical cell, the cathodic chamber comprising a cathode, wherein the cathodic chamber is adjacent to the base swing chamber and separated by a second anion exchange membrane.
C25B 3/09 - Composés contenant au moins un atome d’azote
B01D 53/32 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par effets électriques autres que ceux prévus au groupe
A polarization-sensitive encoder, a polarimetric camera, and a method for polarimetric imaging in which the encoder includes a two-dimensional (2D) polycrystalline photonic-crystal film with nanofiber, multi-scale, self-assembled structures.
G06V 10/147 - Détails de capteurs, p. ex. lentilles de capteurs
G01S 17/74 - Systèmes utilisant la reradiation d'ondes électromagnétiques autres que les ondes radio, p. ex. pour l'identification ami–ennemi
G01S 17/931 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour prévenir les collisions de véhicules terrestres
G06T 7/246 - Analyse du mouvement utilisant des procédés basés sur les caractéristiques, p. ex. le suivi des coins ou des segments
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 20/58 - Reconnaissance d’objets en mouvement ou d’obstacles, p. ex. véhicules ou piétonsReconnaissance des objets de la circulation, p. ex. signalisation routière, feux de signalisation ou routes
H04N 25/71 - Capteurs à dispositif à couplage de charge [CCD]Registres de transfert de charge spécialement adaptés aux capteurs CCD
C07D 251/52 - Deux atomes d'azote avec un atome d'oxygène ou de soufre lié au troisième atome de carbone du cycle
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p. ex. chlorazanil, mélamine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 251/46 - Un atome d'azote avec des atomes d'oxygène ou de soufre liés aux deux autres atomes de carbone du cycle
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
59.
SILYL-LIPID N-ACYL L-HOMOSERINE LACTONES AS QUORUM SENSING MOLECULES
Disclosed are novel silyl-lipid containing N-acylated homoserine lactone compounds. The compounds may be used in quorum sensing and may have desirable agonist or antagonist activity.
This invention provides such new and useful methods and systems for accurately comparing treatment efficacy and safety using heterogeneous clinical trials in the absence of a common control group. To accomplish this, the invention leverages both novel regression techniques and novel simulation techniques to normalize heterogeneous clinical trials to a common background, and to analytically isolate the portion of the patient response specifically attributable to a given treatment and not the placebo effect. The sequential regression and simulation techniques of the disclosed methods and systems further allow for the outcomes of subjects of heterogeneous clinical trials to be simulated as a function of treatment and patient-level features, enabling the creation of decision support tools capable of making personalized treatment recommendations.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
A steerable laser ablation therapy robot for use in minimally invasive neurosurgery is disclosed. The steerable robotic device comprises a rigid straight outer tube; at least one telescopic flexible tendon-driven inner tube, including an outer telescopic flexible tendon-driven inner tube; and an optical fiber extending through the at least one telescopic flexible tendon-driven inner tube, the optical fiber coupled distally to a distal tip of the outer telescopic flexible tendon-driven inner tube and proximally to a laser generator.
A61B 34/00 - Chirurgie assistée par ordinateurManipulateurs ou robots spécialement adaptés à l’utilisation en chirurgie
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61B 18/24 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet avec un cathéter
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61M 25/01 - Introduction, guidage, avance, mise en place ou maintien en position des cathéters
A61M 25/06 - Aiguilles avec un guide pour piquer le corps ou analogues
62.
PRODUCTION OF CHEMICALS BY DIRECT PLASMA CONVERSION OF LIQUID FEEDSTOCKS
A reaction system for carrying out a process for production of chemicals from liquid feedstocks includes a reactor containing one or more liquid reactants, an assembly with two or more electrodes within the reactor configured to generate a high voltage discharge within the one or more liquid reactants, an electrical power supply electrically coupled to the electrodes, inlets and outlets to the reactor for delivering reactants and removing products, and a pressure controller configured to control a pressure of the liquid reactants.
C01B 3/24 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés organiques gazeux ou liquides d'hydrocarbures
C01B 32/05 - Préparation ou purification du carbone non couvertes par les groupes , , ,
C07C 4/08 - Préparations d'hydrocarbures à partir d'hydrocarbures contenant un plus grand nombre d'atomes de carbone par élimination d'une partie aliphatique ou cycloaliphatique de la molécule
63.
VISCOELASTIC MATERIALS BASED ON MICROSTRUCTURED LIQUIDS
The disclosure provides for viscoelastic materials based on microstructured liquids and applications thereof, including as underwater adhesives and wound care, and processes to make the viscoelastic materials.
Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07C 235/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant acyclique et saturé ayant au moins l'un des atomes d'oxygène liés par des liaisons simples, lié de plus à un atome de carbone d'un cycle aromatique à six chaînons, p. ex. phénoxyacétamides ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C07C 317/08 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques d'un squelette carboné acyclique non saturé
C07D 207/14 - Atomes d'azote ne faisant pas partie d'un radical nitro
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C07D 231/40 - Atomes d'azote acylés sur ledit atome d'azote
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
Disclosed herein are therapeutic agents capable of increasing the expression level of an epigenetic marker described herein. Also described herein are therapeutic agents that reduce or slow-down an aging phenotype.
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Provided are methods of analyzing capped ribonucleic acids (RNAs). The methods include translocating an adapted RNA through a nanopore of a nanopore device. The adapted RNA includes an RNA region, a 5′ cap, and an adapter polynucleotide attached to the 5′ cap. The methods include monitoring ionic current through the nanopore during the translocating, translocating the 5′ cap through the nanopore, and identifying one or more ionic current features characteristic of the 5′ cap (e.g., a triphosphate linkage between the 5′ cap and nucleotide N1 of the RNA region, a 5′ to 5′ orientation of the 5′ cap and nucleotide N1 of the RNA region, and/or the like), translocating through the nanopore. Also provided are computer-readable media, computer devices, and systems that find use, e.g., in practicing the methods of the present disclosure.
The present disclosure relates generally to detection on non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
69.
COMPOSITIONS AND METHODS FOR CELL-FREE DNA EPIGENETIC GASTROINTESTINAL CANCER DETECTION AND TREATMENT
Baylor Research Institute d/b/a Baylor Scott & White Research Institute (USA)
Baylor College of Medicine (USA)
The Regents of the University of California (USA)
Inventeur(s)
Goel, Ajay
Li, Wei
Xu, Jianfeng
Abrégé
Provided herein are, inter alia, methods of detecting DNA methylation levels in patients at risk of developing a gastrointestinal cancer, methods of diagnosing a patient with a gastrointestinal cancer based on DNA methylation levels, methods of monitoring DNA methylation levels in patients at risk of developing a gastrointestinal cancer, and methods of treating patients having a gastrointestinal cancer.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
70.
METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF CELL SURFACE PD-L1/L2
Described are methods for enhancing cancer immune surveillance and the efficacy of the treatment of melanoma or non-melanoma cancers such as pancreatic or colorectal cancers, particularly by controlling cancer cell-surface PD-L1/L2 and the E3 ligase ITCH. Also described are methods of inhibiting an adaptive immune resistance response to anti-immune checkpoint protein therapy in a subject. As described herein, the efficacy of MAPK inhibitor therapy is increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2. As further demonstrated herein, the efficacy of anti-PD-1/L1 therapy is also increased by treatment with an activator of E3 ligase ITCH or a destabilizer of cell-surface PD-L1/L2.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present disclosure relates generally to two-dimensional and three-dimensional cultures of cells, the cultures comprising one or a plurality of enteric neurons and/or one or a plurality of enteric glial cells. These cells and cultures can be used for screening compounds for neurologically active compounds, for transplantation into subjects for animal models, and for administration to a subject with a gut motility disorder.
The present disclosure addresses cell type heterogeneity during differentiation of human pluripotent stem cells into islet cells by shifting cell identity from alpha cells to beta cells. More specially, the present disclosure provides a clonal human pluripotent stem cell line that broadly expresses the gene NKX6.1 across cells at the pancreatic progenitor cell stage of in vitro differentiation, which yields fewer alpha cells and more beta cells during directed differentiation to islet cells. The present disclosure further provides a method of improving the yield of insulin-producing cells produced from pluripotent stem cells for transplantation into patients with diabetes.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Compositions and methods of treatment for osteoarthritis and cartilage damage in a subject comprising administering to a subject in need thereof an effective amount of a dihydronicotinamide riboside (NRH). Compositions and methods of treatment for osteoarthritis, cartilage damage, gout or aging-associated diseases in a subject comprising administering to a subject in need thereof an effective amount of NRH and/or nicotinamide riboside (NR) and administering to the subject an effective amount of a purine nucleoside phosphorylase (PNP) inhibitor.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/06 - Agents antigoutte, p. ex. agents antihyperuricémiants ou uricosuriques
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c.-à-d. le conjugué entier étant un co-médicament, p. ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A method for forming a metal oxide includes a step of adding citrate acid to a salt-containing solution to produce a precursor solution. Characteristically, the salt-containing solution includes a neodymium salt or an americium salt. A chilled solution of hexamethylenetetramine (HMTA) and urea is added to a chilled precursor solution to form a citrate gel. Advantageously, citrate gel can be produced with an R-value of 0.5 to 3, wherein the R-value is a molar ratio of HMTA to Nd. The citrate gel is then heated to form the metal oxide of neodymium or americium.
The present disclosure relates generally to detection on non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.
C12Q 1/6874 - Méthodes de séquençage faisant intervenir des réseaux d’acides nucléiques, p. ex. séquençage par hybridation [SBH]
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
The present disclosure provides materials and methods for producing droplet libraries with thousands of distinct reagents. The monodispersed libraries prepared according to the methods provided herein use multiwall plates and are compatible with microfluidic processing.
Methods and systems that pertain to an image reconstruction of motion-corrupted images are disclosed. In some embodiments of the disclosed technology, an image reconstruction method includes obtaining an initial estimate of object boundaries from motion-corrupted images, creating an implicit representation of the motion-corrupted images, updating the implicit representation of the motion-corrupted images using acquired imaging data to generate an updated implicit representation of the motion-corrupted images, and converting the updated implicit representation of the motion corrupted images to an explicit set of motion-corrected images.
G06V 10/26 - Segmentation de formes dans le champ d’imageDécoupage ou fusion d’éléments d’image visant à établir la région de motif, p. ex. techniques de regroupementDétection d’occlusion
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p. ex. des objets vidéo
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
79.
METHOD OF INHIBITING DEGRADING PROTEASE ACTIVITY IN AGING
Provided herein are methods of reversing accumulation of a serine protease. reversing cellular damage. and/or preserving extracellular matrix in an organ of a subject comprising selecting a subject at risk of damage to the organ, and administering a therapeutically effective amount of a serine protease inhibitor. The serine protease inhibitor may be an orally administered competitive inhibitor.
In some embodiments, there is provided a method including receiving, by a machine learning model, first data corresponding to noisy audio including audio of a target speaker of interest proximate to a microphone; receiving, by the machine learning model, second data corresponding to articulatory gestures sensed by the microphone which also detected the noisy audio, wherein the second data corresponding to the articulatory gestures comprises one or more Doppler data indicative of Doppler associated with the articulatory gestures of the target speaker while speaking the audio; combining, by the machine learning model, a first set of features for the first data and a second set of features for the second data to form an output representative of the audio of the target speaker. Related systems, methods, and articles of manufacture are also disclosed.
G10L 21/0224 - Traitement dans le domaine temporel
G10L 15/25 - Reconnaissance de la parole utilisant des caractéristiques non acoustiques utilisant la position des lèvres, le mouvement des lèvres ou l’analyse du visage
G10L 21/0232 - Traitement dans le domaine fréquentiel
81.
COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES
In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-COV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.
Some embodiments of the present disclosure include a digital-to-analog conversion system configured to reduce inter-symbol interference (ISI) in high-speed continuous-time DACs. The system can include a main DAC with multiple sub-DACs, each configured to process a portion of a digital input sequence and generate part of an output waveform. To address ISI errors introduced by the sub-DACs, the system can include an ISI mitigation feedback loop. The ISI mitigation feedback loop can include an analog-to-digital converter (ADC) that generates a digital sequence from the output waveform and an analog correction signal generated by a correction DAC. A fractional decimation filter can be used to adjust a sampling rate and attenuate high-frequency components. A digital error estimator can generate an error cancellation sequence by correlating encoder information with the input sequence. The correction DAC can use the error cancellation sequence to generate the analog correction signal.
A stent system and method to prevent stent migration. The stent system includes a magnetic stent comprising an outer surface and an inner surface, a proximal end, and a distal end with three or more magnets disposed thereon and configured to form a ring. The system may further have a magnetic ring comprising three or more magnets configured to form a ring. The magnetic ring is disposed proximally or distally to the magnetic stent, which allows magnetic repulsion to maintain the position of the stent.
A61F 2/90 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles caractérisés par une structure de type filet ou de type à mailles
84.
HARMONIC MIXER WITH MULTI-PHASE LOCAL OSCILLATOR SIGNALS FOR INHERENTLY LINEAR UPCONVERSION
Disclosed are example embodiments of harmonic mixer. The harmonic mixer including a multi-phase LO signal generator. Each phase of the multi-phase LO signal generator outputting an LO signal on a signal line. The harmonic mixer including a plurality of mixers. Each mixer of the plurality of mixers connected to a signal line. The mixer driven by an IF. The harmonic mixer including an output network coupled to the outputs of the plurality of mixers.
H03D 7/12 - Transfert de modulation d'une porteuse à une autre, p. ex. changement de fréquence au moyen de dispositifs à semi-conducteurs ayant plus de deux électrodes
Ferrocene (Fc)-substituted organometallic complexes are described. In one example, an Fc-substituted organometallic complex has a structure represented by formula IV:
2 is 4-ferrocenylphenyl. Non-aqueous redox flow batteries and electrical energy storage systems comprising the Fe-substituted organometallic complexes and methods of storing energy using the Fe-substituted organometallic complexes are provided.
There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.
C07H 5/10 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure au soufre, au sélénium ou au tellure au soufre
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.
C07H 5/10 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure au soufre, au sélénium ou au tellure au soufre
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
There are provided, inter alia, compositions including a scintillator nanocrystal linked to a chemical agent moiety through a scintillator-activated photocleavable linker, and methods of use thereof.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
89.
ACTIVE CURING SYSTEMS AND METHODS FOR CONCRETE MANUFACTURING BY CARBON DIOXIDE SEQUESTRATION
Provided herein are active flow-through carbonation curing systems useful for contacting carbon dioxide (CO2) gas streams with concrete materials under ambient pressure. This contacting causes a carbonation reaction in which CO2 forms materials, such as, but not limited to, calcium carbonate (CaCO3). The methods include, but are not limited to, contacting a conditioned flue gas containing CO2 inside of a carbonation chamber with green bodies or concrete components in which flue gas properties such as temperature, relative humidity, flow rate, and flow direction, are self-adjusted during the curing process based on a self-sensing instrumentation system inside a curing chamber and carbonation kinetic regression model. This system improves CO2 capture efficiency and material performance while reducing processing energy.
Compositions, manufacturing processes, articles of manufacture, and structures/batteries for self-forming batteries and self-healing solid electrolytes are disclosed. Example embodiments include a self-forming battery. The battery may include a first electrode material and a second electrode material. Assembly of the two electrode materials may result in a chemical reaction that forms an electrolyte layer between the two electrode materials.
H01M 10/0585 - Structure ou fabrication d'accumulateurs ayant uniquement des éléments de structure plats, c.-à-d. des électrodes positives plates, des électrodes négatives plates et des séparateurs plats
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
H01M 4/587 - Matériau carboné, p. ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers
H01M 10/056 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p. ex. électrolytes mixtes inorganiques/organiques
A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Compounds, pharmaceutical compositions, kits, and methods for treating gut motility disorders are herein. Examples of gut motility disorders to which the compounds, pharmaceutical compositions, kits, and methods are directed include achalasia, Hirschspmng's disease, an intestinal pseudo-obstruction, gastroesophageal reflux disease (GERD), functional dysphagia, functional dyspepsia, irritable bowel syndrome (IBS), gastroparesis, functional constipations, functional diarrhea, and fecal incontinence. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/4174 - Arylalkylimidazoles, p. ex. oxymétazoline, naphazoline, miconazole
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
93.
LASER MICROMACHINING OF MEMS RESONATORS FROM BULK OPTICALLY TRANSPARENT MATERIAL
Systems, processes and devices are provided for laser-based manufacturing of resonators and MEMS devices from bulk material including optically transparent material. Processes include digital marking of resonator structures in bulk material through non-linear interaction of ultrafast laser beam inscribing and material. The resonator structure may be defined and released through selective wet etching of the laser-modified areas, utilizing a combination of basic and acidic aqueous solutions. Processes can also include hydrofluoric thinning prior to wet etching to prevent laser surface damages. Systems and processes can pattern and fabricate resonator structures and concentricring structures. Embodiments provide miniaturized vibratory sensors from low loss material, such as fused silica and quartz, with an improved resolution and accuracy of measurements for inertial sensing, time referencing, bio-sensing and acoustic sensing.
Natural killer (NK) cells are innate lymphocytes that possess traits of adaptive immunity, such as memory formation. However, the molecular mechanisms by which NK cells persist to form memory cells are not well understood. Using single cell RNA sequencing, we identified two distinct effector NK cell (NKeff) populations following mouse cytomegalovirus (MCMV) infection. Ly6C− memory precursor (MP) NK cells displayed enhanced survival during the contraction phase in a Bcl2-dependent manner, and differentiated into Ly6C+ memory NK cells. Our studies show that a NK cell-intrinsic checkpoint is controlled by the transcription factor Fli1 which limits MP NK formation by regulating early effector NK cell fitness during viral infection. Building upon this discovery, we have designed methods and materials for modulating the molecular mechanisms that regulate memory cell fate in NK cells, such as genetically modified NK cells having a deletion in the gene for the transcription factor Fli1.
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
Repolyols can be quickly produced by combining fragments of a polyurethane product which with a reagent which is an organic acid or an anhydride of the organic acid or a mixture thereof to form a reaction mixture, and heating the reaction mixture to a reaction temperature greater than a melting point of the reagent for a reaction time of no greater than two hours. The organic acid comprises two carboxylic acid groups linked to each other through a linking group having two or three carbon atoms in the linking chain. The anhydride can include a 5 or 6 member cyclic structure with the group —C(O)—O—C(O)—.
C08J 11/26 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance organique par traitement avec des composés organiques contenant de l'oxygène contenant des groupes acide carboxylique, leurs anhydrides ou esters
96.
Compositions and Methods for Inhibiting and Treating Coronavirus Infections
Disclosed herein are methods of using one or more mitochondrial targeted antioxidants, such as mitoquinol or mitoquinone, to prevent, inhibit, and/or treat infections and symptoms caused by infection by a coronavirus, such as SARS-CoV-2.
Provided herein, inter alia, are compositions including viruses and nucleic acids having promoters capable of expressing multiple heterologous nucleic acids. The compositions are particularly useful for delivering and expressing heterologous nucleic acids in neurons. With respect to the nervous system, neural tissue, and neurons, the compositions listed herein are contemplated to be effective for treatment of retinal neurodegenerative diseases.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Described herein are methods and compositions to treat arthritis, fibrosis and cancer by inhibiting RPTPα clustering. Included are methods and compositions for the diagnosis of RPTPα clustering.
Synthetic genetic polymers (XNAs) have the potential to transition aptamers from laboratory tools to therapeutic agents, but additional functionality is needed to compete with antibodies. The present invention features compositions and methods that utilizes a biologically stable artificial genetic system comprised of α-L-threofuranosyl nucleic acid (TNA). This system facilitates the production of backbone- and base-modified aptamers termed ‘threomers’ that function as high quality protein capture reagents.
Presented are methods and compositions for obtaining sequence information from one or more individual cells. The methods are useful for obtaining sequence information for a single nucleotide sequence, and for multiplex generation of sequence information from one or more individual cells.
brevets
